The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple Sclerosis
Open accessAbstract
BACKGROUND: B cells are implicated in the pathogenesis of multiple sclerosis. A beneficial effect of B-cell depletion using rituximab has been shown, but the complete mechanism of action for this drug is unclear. OBJECTIVE: To determine the relationship between T and B cells and changes in cerebrospinal fluid (CSF) chemokine levels with rituximab, a monoclonal antibody that targets CD20. DESIGN: Phase 2 trial of rituximab as an add-on therapy. SETTING: The John L. Trotter Multiple Sclerosis Center, Washington University. Participants and Intervention Thirty subjects who had relapsing-remitting multiple sclerosis with clinical and magnetic resonance imaging activity despite treatment with an immunomodulatory drug received 4 weekly doses of rituximab (375 mg/m(2)). MAIN OUTCOME MEASURES: Lumbar puncture was performed before and after rituximab infusions in 26 subjects. Levels of B and T lymphocytes in the CSF were enumerated by flow cytometry, and chemoattractant levels were measured by enzyme-linked immunosorbent assay. RESULTS: After rituximab administration, CSF B-cell levels were decreased or undetectable in all subjects, and CSF T-cell levels were reduced in 21 subjects (81%). The mean reduction in CSF cellularity was 95% for B cells and 50% for T cells. After rituximab infusion, CSF CXCL13 and CCL19 levels decreased (P = .002 and P = .03, respectively). The proportional decline in CSF T-cell levels correlated with the proportional decrease in CXCL13 levels (r = 0.45; P = .03), suggesting a possible relationship. The CSF IgG index, IgG concentration, and oligoclonal band number were unchanged following treatment. CONCLUSIONS: In subjects with multiple sclerosis, B cells are critical for T-cell trafficking into the central nervous system and may alter the process by influencing chemokine production within the central nervous system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Magliozzi, R., Howell, O., Vora, A., Serafini, B., Nicholas, R., Puopolo, M., Reynolds, R., & Aloisi, F. (2006) · Brain · doi:10.1093/brain/awm038 · Cited by 1,443
A chemokine-driven positive feedback loop organizes lymphoid follicles
Ansel, K. M., Ngo, V. N., Hyman, P. L., Luther, S. A., Förster, R., Sedgwick, J. D., Browning, J. L., Lipp, M., & Cyster, J. G. (2000) · Nature · doi:10.1038/35018581 · Cited by 1,278
Serafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E., & Aloisi, F. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00049.x · Cited by 1,208
Chemokines and Cell Migration in Secondary Lymphoid Organs
Cyster, J. G. (1999) · Science · doi:10.1126/science.286.5447.2098 · Cited by 1,031
Fischer, J. S., Rudick, R. A., Cutter, G. R., Reingold, S. C., & National MS Society Clinical Outcomes Assessment Task Force (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500409 · Cited by 993
Legler, D. F., Loetscher, M., Roos, R. S., Clark-Lewis, I., Baggiolini, M., & Moser, B. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.4.655 · Cited by 837
Distinct Patterns of Multiple Sclerosis Pathology Indicates Heterogeneity in Pathogenesis
Lucchinetti, C. F., Brück, W., Rodriguez, M., & Lassmann, H. (1996) · Brain Pathology · doi:10.1111/j.1750-3639.1996.tb00854.x · Cited by 733
Lymphoid Neogenesis in Rheumatoid Synovitis
Takemura, S., Braun, A., Crowson, C., Kurtin, P. J., Cofield, R. H., O’Fallon, W. M., Goronzy, J. J., & Weyand, C. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.2.1072 · Cited by 660
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo
Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M., & Golay, J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1581 · Cited by 576
Krumbholz, M., Theil, D., Cepok, S., Hemmer, B., Kivisäkk, P., Ransohoff, R. M., Hofbauer, M., Farina, C., Derfuss, T., Hartle, C., et al. (2006) · Brain · doi:10.1093/brain/awh680 · Cited by 561
Ngo, V. N., Korner, H., Gunn, M. D., Schmidt, K. N., Sean Riminton, D., Cooper, M. D., Browning, J. L., Sedgwick, J. D., & Cyster, J. G. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.2.403 · Cited by 553
Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial
Bar‐Or, A., Calabresi, P. A. J., Arnold, D., Markowitz, C., Shafer, S., Kasper, L. H., Waubant, E., Gazda, S., Fox, R. J., Panzara, M., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21363 · Cited by 527
Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients
Cross, A. H., Stark, J. L., Lauber, J., Ramsbottom, M. J., & Lyons, J.-A. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.06.029 · Cited by 454
Self-citationPrineas, J. W., & Rg, W. (1978) · PubMed · Cited by 417
Demidem, A., Lam, T., Alas, S., Hariharan, K., Hanna, N., & Bonavida, B. (1997) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1997.12.177 · Cited by 394
Link, H., & Tibbling, G. (1977) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365517709091498 · Cited by 372
Fu, Y.-X., Huang, G., Wang, Y., & Chaplin, D. D. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.7.1009 · Cited by 300
B cells and antibodies in CNS demyelinating disease
Cross, A. H., Trotter, J. L., & Lyons, J.-A. (2001) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(00)00409-4 · Cited by 251
Self-citationPrineas, J. W. (1979) · Science · doi:10.1126/science.424741 · Cited by 242
B cells as therapeutic targets in autoimmune neurological disorders
Dalakas, M. C. (2008) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0901 · Cited by 202
B Lymphocytes as Antigen-Presenting Cells for CD4+ T Cell Priming In Vivo
Constant, S. L. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.5695 · Cited by 200
Giunti, D., Borsellino, G., Benelli, R., Marchese, M., Capello, E., Valle, M. T., Pedemonte, E., Noonan, D., Albini, A., Bernardi, G., et al. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.1202598 · Cited by 182
Multiple sclerosis: Measurement and validation of central nervous system IgG synthesis rate
Tourtellotte, W. W., Potvin, A. R., Fleming, J. O., Murthy, K. N., Levy, J., Syndulko, K., & Potvin, J. H. (1980) · Neurology · doi:10.1212/wnl.30.3.240 · Cited by 170
Manzo, A., Vitolo, B., Humby, F., Caporali, R. F., Jarrossay, D., Dell’Accio, F., Ciardelli, L. M., Uguccioni, M., Montecucco, C., & Pitzalis, C. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23966 · Cited by 148
Rituximab-induced B cell depletion in autoimmune diseases: Potential effects on T cells
Liossis, S. C., & Sfikakis, P. P. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.01.011 · Cited by 147
Krumbholz, M., Theil, D. J., Steinmeyer, F., Cepok, S., Hemmer, B., Hofbauer, M., Farina, C., Derfuss, T. J., Junker, A., Arzberger, T., et al. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2007.07.024 · Cited by 143
Oligoclonal Band Number as a Marker for Prognosis in Multiple Sclerosis
Avasarala, J., Cross, A. H., & Trotter, J. L. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.2044 · Cited by 130
Self-citationElectron microscopy and immunoperoxidase studies of early multiple sclerosis lesions
Prineas, J. W., & Raine, C. S. (1976) · Neurology · doi:10.1212/wnl.26.6_part_2.29 · Cited by 112
CXC Chemokine Ligand 13 Plays a Role in Experimental Autoimmune Encephalomyelitis
Bagaeva, L. V., Rao, P., Powers, J. M., & Segal, B. M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.12.7676 · Cited by 110
BLC (CXCL13) is expressed by different dendritic cell subsets in vitro and in vivo
Vissers, J. L. M., Hartgers, F. C., Lindhout, E., Figdor, C. G., & Adema, G. J. (2001) · European Journal of Immunology · Cited by 96
Pashenkov, M. V., Söderström, M. B., & Link, H. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00441-1 · Cited by 92
Cabezas, S. C., Griguoli, M., Rosicarelli, B., Magliozzi, R., Ria, F., Serafini, B., & Aloisi, F. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.06.015 · Cited by 86
B Cell Chemoattractant CXCL13 Is Preferentially Expressed by Human Th17 Cell Clones
Takagi, R., Higashi, T., Hashimoto, K., Nakano, K., Mizuno, Y., Okazaki, Y., & Matsushita, S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.186 · Cited by 81
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
BOURDETTE, D. N., & Yadav, V. (2008) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-008-0064-4 · Cited by 69
Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis
Harp, C. T., Lovett‐Racke, A. E., Racke, M. K., Frohman, E. M., & Monson, N. L. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.05.002 · Cited by 69
Diagnostic criteria for primary progressive mutiple sclerosis: a position paper.
(2000) · Pure Amsterdam UMC · doi:10.1002/1531-8249(200006)47:6 · Cited by 2
Cited by
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 658
Nylander, A., & Hafler, D. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58649 · Cited by 495
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
Faissner, S., Plemel, J. R., Gold, R., & Yong, V. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0035-2 · Cited by 459
Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy
Li, R., Rezk, A., Miyazaki, Y., Hilgenberg, E., Touil, H., Shen, P., Moore, C. S., Michel, L., Althekair, F., Rajasekharan, S., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab4176 · Cited by 453
Metadata
- Authors
- Piccio, L., Naismith, R. T., Trinkaus, K., Klein, R. S., Parks, B. J., Lyons, J. A., & Cross, A. H.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2010-06-01
- Volume
- 67
- Issue
- 6
- Pages
- 707-14
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2110846578
- Cited by
- 274
- References
- 38
- FWCI
- 11.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.